XORTX Therapeutics Inc. Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Share capital and reserves - Fair value of the warrants issued (Details)	12 Months Ended
	Dec. 31, 2025 CAD ($)	Dec. 31, 2024 CAD ($) USD ($) $ / shares Y
Share capital and reserves
Fair value of the warrants	$ 0	$ 1,205,000
Dividend yield \| Warrants
Share capital and reserves
Significant unobservable input, liabilities		0
Annualized volatility \| Minimum \| Warrants
Share capital and reserves
Significant unobservable input, liabilities		1.30
Annualized volatility \| Maximum \| Warrants
Share capital and reserves
Significant unobservable input, liabilities		1.35
Share price \| Minimum \| Warrants
Share capital and reserves
Significant unobservable input, liabilities		3.03
Share price \| Maximum \| Warrants
Share capital and reserves
Significant unobservable input, liabilities \| $ / shares		3.4
Risk-free interest rate \| Minimum \| Warrants
Share capital and reserves
Significant unobservable input, liabilities		0.0428
Risk-free interest rate \| Maximum \| Warrants
Share capital and reserves
Significant unobservable input, liabilities		0.0433
Expected life \| Warrants
Share capital and reserves
Significant unobservable input, liabilities \| Y		2